(1S,4S)-tert-butyl 5-(4-bromophenyl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate | 942190-76-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: (1S,4S)-tert-butyl 5-(4-bromophenyl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate
• 英文别名: tert-butyl (1S,4S)-5-(4-bromophenyl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate；(S,S)-5-(4-bromo-phenyl)-2,5-diaza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester
• CAS: 942190-76-3
• 化学式: C₁₆H₂₁BrN₂O₂
• 分子量: 353.259
• InChiKey: IMOSZFOPDXMMIY-KBPBESRZSA-N

物化性质

• 熔点：
  210-211 °C
• 沸点：
  440.1±40.0 °C(Predicted)
• 密度：
  1.385±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  32.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (1S,4S)-tert-butyl 5-(4-bromophenyl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate 在 盐酸 、 四(三苯基膦)钯 、 三乙酰氧基硼氢化钠 、 sodium carbonate 作用下， 以 1,4-二氧六环 、 甲醇 、 水 、 1,2-二氯乙烷 、 乙腈 为溶剂， 反应 20.0h， 生成 (1S,4S)-2-methyl-5-(4-(pyridin-3-yl)phenyl)-2,5-diazabicyclo[2.2.1]heptane
  参考文献：
  名称：

  Structure–activity relationship studies of SEN12333 analogues: Determination of the optimal requirements for binding affinities at α7 nAChRs through incorporation of known structural motifs

  摘要：

  Alpha7 nicotinic acetylcholine receptors (nAChRs) have implications in the regulation of cognitive processes such as memory and attention and have been identified as a promising therapeutic target for the treatment of the cognitive deficits associated with schizophrenia and Alzheimer's disease (AD). Structure affinity relationship studies of the previously described alpha 7 agonist SEN12333 (8), have resulted in the identification of compound 45, a potent and selective agonist of the alpha 7 nAChR with enhanced affinity and improved physicochemical properties over the parent compound (SEN12333, 8). (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2015.03.025
• 作为产物：
  描述：

  1,4-二溴苯 、 (1S,4S)-2-Boc-2,5-二氮双环[2.2.1]庚烷 在 tris-(dibenzylideneacetone)dipalladium(0) 、 potassium tert-butylate 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 作用下， 以 甲苯 为溶剂， 反应 16.0h， 以82%的产率得到(1S,4S)-tert-butyl 5-(4-bromophenyl)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate
  参考文献：
  名称：

  Structure–activity relationship studies of SEN12333 analogues: Determination of the optimal requirements for binding affinities at α7 nAChRs through incorporation of known structural motifs

  摘要：

  Alpha7 nicotinic acetylcholine receptors (nAChRs) have implications in the regulation of cognitive processes such as memory and attention and have been identified as a promising therapeutic target for the treatment of the cognitive deficits associated with schizophrenia and Alzheimer's disease (AD). Structure affinity relationship studies of the previously described alpha 7 agonist SEN12333 (8), have resulted in the identification of compound 45, a potent and selective agonist of the alpha 7 nAChR with enhanced affinity and improved physicochemical properties over the parent compound (SEN12333, 8). (C) 2015 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2015.03.025

文献信息

• NOVEL PIPERAZINO-DIHYDROTHIENOPYRIMIDINE DERIVATIVES
  申请人：Pouzet Pascale

  公开号：US20110046096A1

  公开（公告）日：2011-02-24

  The invention relates to the novel dihydrothienopyrimidine sulfoxides of formula (I) and to the pharmacologically acceptable salts thereof, wherein X represents SO or SO 2 , preferably however SO, and wherein R 3 , R 4 , R 4′ , R 5 , R 6 and R 7 are defined as in claim 1 . The invention also relates to pharmaceutical compositions containing said compounds. The novel dihydrothienopyrimidine sulfoxides are suitable for use in the treatment of respiratory or gastrointestinal disorders or diseases, inflammatory diseases of the joints, the skin or the eyes, diseases of the peripheral or central nervous system or cancers.

  该发明涉及公式（I）的新型二氢噻吡嘧啶砜氧化物及其药理学上可接受的盐，其中X代表SO或SO2，但最好是SO，其中R3、R4、R4'、R5、R6和R7如权利要求1中定义。该发明还涉及含有所述化合物的药物组合物。这种新型二氢噻吡嘧啶砜氧化物适用于治疗呼吸系统或消化系统的紊乱或疾病，关节、皮肤或眼睛的炎症性疾病，外周或中枢神经系统的疾病或癌症。
• Novel compounds that are ERK inhibitors
  申请人：Cooper Alan B.

  公开号：US20090118284A1

  公开（公告）日：2009-05-07

  Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

  本发明公开了式1.0的ERK抑制剂及其药学上可接受的盐、酯和溶剂化物。其中，Q是一个带有桥或融合环的哌啶或哌嗪环。哌啶环中可以在环上具有双键。所有其他取代基如本文所定义。本发明还公开了使用式1.0的化合物治疗癌症的方法。
• Compounds that are ERK inhibitors
  申请人：Schering Corporation

  公开号：US07807672B2

  公开（公告）日：2010-10-05

  Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substituents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

  公开的是式子1.0的ERK抑制剂及其药学上可接受的盐和溶剂。Q是一个带有桥或融合环的哌啶或哌嗪环。哌啶环中可以在环中有双键。所有其他取代基的定义如本文所述。还公开了使用式子1.0的化合物治疗癌症的方法。
• HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS
  申请人：Sun Robert

  公开号：US20110038876A1

  公开（公告）日：2011-02-17

  Disclosed are the ERK inhibitors of formula 1.0: [Formula (1.0)] and the pharmaceutically acceptable salts, esters and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

  本发明涉及公开的ERK抑制剂，其化学式为1.0：[Formula (1.0)]及其药学上可接受的盐、酯和溶剂化物。其中，Q是一个可具有桥或融合环的哌啶或哌嗪环。哌啶环中可以在环中具有双键。所有其他取代基均如所定义。本发明还公开了使用化合物1.0治疗癌症的方法。
• WO2007/70398
  申请人：——

  公开号：——

  公开（公告）日：——